Skip to content
Skip to navigation menu
16 October 2013
Researchers at Cardiff University have created a peptide (a small piece of protein), linked to a light-responsive dye, capable of switching 'on’ death pathways in cancer cells. The peptide remains inactive until exposed to external light pulses which convert it into a cell death signal.Complex mechanisms in healthy cells normally protect us from developing cancer. However, when the finely balanced networks of interactions between proteins that control such mechanisms are disturbed, uncontrolled cell growth can occur. The Cardiff team has developed a peptide-switch to alter critical interactions in B-cell lymphoma cancer cells in a ‘smart’ and controlled way. This new pathway activation technology, called transient photoactivation, may enable scientists to identify cells normally resistant to chemotherapy leading to the development of more effective treatment strategies.Professor Rudolf Allemann from Cardiff University’s School of Chemistry, who led the research, said:"Whilst killing cancer cells is a goal in itself, this is also proof of a wider principle. Directing therapeutic peptides to the precise location where they are required can be difficult, but activating peptides with light will allow us to precisely define the area where we wish a peptide to act. "Our research demonstrates that we can control cellular processes with light, which has implications for research in biology and medicine, as our tools can be used to understand the inner workings of cells and to work out how to correct misfiring pathways that lead to disease. "This work may eventually lead to photo-controlled drugs and tools to probe molecular interactions in intact cells and whole organisms with enormous consequences for biomedical research."This research required the combined expertise of scientists from three Schools at Cardiff (Chemistry, Medicine, and Pharmacy and Pharmaceutical Sciences), who contributed different perspectives and techniques to develop this technology. The findings are published in the journal Molecular Biosystems and can be accessed by clicking here.The work was funded by an Engineering and Physical Sciences Research Council (EPSRC) grant worth £1.4M. /EndsUseful links: The School of ChemistryThe School of MedicineThe School of Pharmacy and Pharmaceutical Sciences
Tomas Llewelyn BarrettPublic Relations Cardiff University Tel: 029 20 875 596 Mobile: 07950792532E-mail: BarrettTL1@cardiff.ac.ukCardiff UniversityCardiff University is recognised in independent government assessments as one of Britain’s leading teaching and research universities and is a member of the Russell Group of the UK’s most research intensive universities. Among its academic staff are two Nobel Laureates, including the winner of the 2007 Nobel Prize for Medicine, University Chancellor Professor Sir Martin Evans. Founded by Royal Charter in 1883, today the University combines impressive modern facilities and a dynamic approach to teaching and research. The University’s breadth of expertise encompasses: the College of Humanities and Social Sciences; the College of Biomedical and Life Sciences; and the College of Physical Sciences, along with a longstanding commitment to lifelong learning. Cardiff's three flagship Research Institutes are offering radical new approaches to neurosciences and mental health, cancer stem cells and sustainable places.
This is an externally hosted beta service offered by Google.